Vaccitech
2016
FOUNDED
PRIVATE
STATUS
Grant
LATEST DEAL TYPE
$8.5M
LATEST DEAL AMOUNT
11
INVESTORS
Description
Developer of therapeutic vaccine technology created for the treatment of seasonal flu and prostate cancer. The company's therapeutic vaccine technology includes live-attenuated, killed whole-cell and subunit antigen vaccines that deliver either one or two heterologous viral vector vaccines, each encoding the same antigen, several weeks to months apart, enabling patients to improve the protection provided by the seasonal flu vaccination.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- The Schrodinger Building Heatley Road
- The Oxford Science Park
- Oxford OX4 4GE
- England, United Kingdom
+44 01865 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Vaccitech’s full profile, request a free trial.
Vaccitech Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 07-Mar-2019 | $8.5M | 0000 | Completed | Clinical Trials - Phase 2 | |
| 3. Early Stage VC | 20-Dec-2018 | 00.000 | 0000 | 000.00 | Completed | Clinical Trials - Phase 2 |
| 2. Early Stage VC (Series A) | 14-Jan-2018 | $27M | $41.4M | Completed | Clinical Trials - Phase 2 | |
| 1. Seed Round | 10-May-2016 | $14.4M | $14.4M | 000.00 | Completed | Product Development |
Vaccitech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000 | 00.000000 | 00000.00 | 00000.00 | 00 | 00000.00 | 0.000 | |
| Series A | 00,000 | 00.000000 | 00000.00 | 00000.00 | 00 | 00000.00 | 00.000 | |
| Ordinary | 13,333 | $0.012718 | $953.81 | $953.81 | 1x | $953.81 | 31.86% | |
| Ordinary | 133 | $0.012718 | $956.2 | $956.2 | 1x | $956.2 | 0.32% |
Vaccitech Competitors (35)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Turnstone Biologics | Venture Capital-Backed | Ottawa, Canada | 00 | 00000 | 000000000000 | 00000 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000000 | Formerly VC-backed | Culver City, CA | 000 | 00000 | 00000000000 | 00000 |
| 00000000 | Venture Capital-Backed | Uppsala, Sweden | 00 | 0000000000 | ||
| 000 0000000000000 | Formerly VC-backed | Princeton, NJ | 00 | 00.000 | 000000 - 000 | 00.000 |
Vaccitech Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Biomedical Advanced Research and Development Authority | Corporation | 000 0000 | 000000 0 | |||
| Genematrix | Corporation | Minority | 000 0000 | 000000 0 | ||
| Korea Investment Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| GV | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Neptune Restaurant Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Vaccitech Executive Team (6)
You’re viewing 5 of 6 executives. Get the full list »Vaccitech Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Adrian Hill | Vaccitech | Co-Founder & Board Member | 000 0000 | |
| Andrew McLean MD | Oxford Sciences Innovation | Board Member | 000 0000 | |
| Pierre Morgon | Self | Board Member | 000 0000 | |
| Robin Wright | Self | Chairman | 000 0000 | |
| Steven Chatfield Ph.D | Self | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 7 board members. Get the full list »